Chandra Bhagat Pharma P/E Ratio
Current P/E Ratio
9.9
Low Valuation
Very Low - Potentially undervalued or facing challenges
Chandra Bhagat Pharma P/E ratio. Chandra Bhagat Pharma (CBPL) P/E ratio is 9.9 (Low), EPS (TTM) ₹4.04, current price ₹ on None — Very Low - Potentially undervalued or facing challenges. Also explore Chandra Bhagat Pharma share price performance to track price trends across different timeframes.
Current Valuation Metrics
P/E Ratio
9.9
Current Price
₹
EPS (TTM)
₹4.04
Exchange
None
Valuation Signal
Signal
Undervalued
Sector Context
Sector Average
55.06
Sector Median
32.04
Sector Rank
#11 of 200
Sector Percentile
5.5%
CBPL P/E Ratio — Valuation Signal & Historical Context
Chandra Bhagat Pharma P/E 9.9 — signal: Undervalued. For live price, revenue and the complete fundamental profile, see Chandra Bhagat Pharma share price screener.
- Stock appears undervalued with PE of 9.9, suggesting potential buying opportunity
- Trading at discount to sector average PE of 55.06
CBPL vs Healthcare Peers — P/E Ratio Comparison
Chandra Bhagat Pharma P/E 9.9 vs Healthcare average 55.06, median 32.04 — range 2.02–722.21.
Sector Average
55.06
Sector Median
32.04
Lowest P/E
2.02
Highest P/E
722.21
Companies
200
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.02 | ₹60 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.33 | ₹55 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.86 | ₹6,006 | Low |
| Dipna Pharmachem | DPL | 3.97 | ₹11 | Low |
| JFL Life Sciences | JFLLIFE | 5.05 | ₹65 | Low |
| Royal Sense | ROYAL | 5.39 | ₹40 | Low |
| Kabra Drugs | KABRADG | 5.47 | ₹41 | Low |
| GKB Ophthalmics | GKB | 5.85 | ₹32 | Low |
| Colinz Laboratories | COLINZ | 6.31 | ₹18 | Low |